NCT03546829View on ClinicalTrials.gov

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Early Stage Non-Small Cell Lung Cancer
Interventions
DRUG

Vancomycin

125 mg, 4x daily for 5 weeks

RADIATION

Precision hypofractionated radiation

Patients planned to undergo precision hypofractionated radiation to all sites of oligoprogression and will receive vancomycin for 1 week before RT and for 1 month after start of RT, and asked to provide stool and blood samples as outlined in the Safety Trial study table.

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT03546829 - Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter